January 2020 — Cellular Therapy

By MCL Education • January 14, 2020

Share this:

Chimeric antigen receptor T cells (CAR T cells) represent an exciting new area of cellular therapy. Manufacturing autologous CAR T cells involves virally transducing a patient’s T cells to express a receptor to heighten recognition of tumor-specific antigens. From a regulatory standpoint, CAR T cells are subject to regulation both as a drug and as a biological product. This presents ongoing challenges for cellular therapy programs and laboratories that seek to develop in-house manufacturing of next-generation CAR T cell products.

	Ashley Krull, Ph.D. Fellow, Cellular Therapy Mayo Clinic @AshleyAKrull
	Allan Dietz, Ph.D. Consultant, Transfusion Medicine Mayo Clinic Associate Professor of Laboratory Medicine and Pathology Instructor in Biochemistry and Molecular Biology Mayo Clinic College of Medicine and Science

MCL Education

This post was developed by our Education and Technical Publications Team.